MCID: DYS011
MIFTS: 39

Dyskinesia of Esophagus

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyskinesia of Esophagus

MalaCards integrated aliases for Dyskinesia of Esophagus:

Name: Dyskinesia of Esophagus 12 15
Esophageal Motility Disorders 55 44 73
Esophageal Motility Disorder 12
Oesophageal Motor Disorder 12
Dyskinesia of Oesophagus 12
Oesophageal Dysmotility 12
Esophageal Dysmotility 12
Esophageal Spasm 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9192
ICD10 33 K22.4
ICD9CM 35 530.5
MeSH 44 D015154

Summaries for Dyskinesia of Esophagus

MalaCards based summary : Dyskinesia of Esophagus, also known as esophageal motility disorders, is related to crest syndrome and esophagitis, eosinophilic, 1, and has symptoms including spasm An important gene associated with Dyskinesia of Esophagus is TEF (TEF, PAR BZIP Transcription Factor). The drugs Lansoprazole and Menthol have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and bone.

Related Diseases for Dyskinesia of Esophagus

Diseases related to Dyskinesia of Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 crest syndrome 30.6 AGBL3 CENPB TOP1 UBTF
2 esophagitis, eosinophilic, 1 30.6 ATP12A ATP4A
3 fungal esophagitis 10.6 ATP12A ATP4A
4 bladder calculus 10.6 ATP12A ATP4A
5 gastrointestinal neuroendocrine benign tumor 10.6 ATP12A ATP4A
6 neonatal candidiasis 10.6 ATP12A ATP4A
7 photoallergic dermatitis 10.6 ATP12A ATP4A
8 squamous papillomatosis 10.6 ATP12A ATP4A
9 acute laryngitis 10.6 ATP12A ATP4A
10 gastroduodenal crohn's disease 10.6 ATP12A ATP4A
11 gastric neuroendocrine neoplasm 10.6 ATP12A ATP4A
12 toxic megacolon 10.6 ATP12A ATP4A
13 aspiration pneumonitis 10.6 ATP12A ATP4A
14 postsurgical hypothyroidism 10.6 ATP12A ATP4A
15 esophageal candidiasis 10.6 ATP12A ATP4A
16 duodenitis 10.6 ATP12A ATP4A
17 rumination disorder 10.6 ATP12A ATP4A
18 bile reflux 10.6 ATP12A ATP4A
19 granulomatous gastritis 10.6 ATP12A ATP4A
20 active peptic ulcer disease 10.6 ATP12A ATP4A
21 laryngeal disease 10.6 ATP12A ATP4A
22 ischemic neuropathy 10.6 ATP12A ATP4A
23 capillary disease 10.6 ATP12A ATP4A
24 peptic esophagitis 10.6 ATP12A ATP4A
25 duodenal disease 10.6 ATP12A ATP4A
26 hernia, hiatus 10.6 ATP12A ATP4A
27 congenital disorder of deglycosylation 10.6 ATP12A ATP4A
28 anismus 10.6 ATP12A ATP4A
29 laryngitis 10.6 ATP12A ATP4A
30 laryngeal tuberculosis 10.6 ATP12A ATP4A
31 lymphocytic colitis 10.5 ATP12A ATP4A
32 clostridium difficile colitis 10.5 ATP12A ATP4A
33 lower urinary tract calculus 10.5 ATP12A ATP4A
34 diarrhea 1, secretory chloride, congenital 10.5 ATP12A ATP4A
35 chronic laryngitis 10.5 ATP12A ATP4A
36 chronic intestinal vascular insufficiency 10.5 ATP12A ATP4A
37 eosinophilic gastritis 10.5 ATP12A ATP4A
38 polyposis, skin pigmentation, alopecia, and fingernail changes 10.5 ATP12A ATP4A
39 esophageal varix 10.5 ATP12A ATP4A
40 esophagus adenocarcinoma 10.5 ATP12A ATP4A
41 myopathy, x-linked, with excessive autophagy 10.5 ATP12A ATP4A
42 gastric lymphoma 10.5 ATP12A ATP4A
43 pancreatic steatorrhea 10.5 ATP12A ATP4A
44 superior mesenteric artery syndrome 10.4 ATP12A ATP4A
45 esophagitis 10.4
46 jejunoileitis 10.4 ATP12A ATP4A
47 functional gastric disease 10.4 ATP12A ATP4A
48 lateral medullary syndrome 10.4 ATP12A ATP4A
49 paine syndrome 10.4 ATP12A ATP4A
50 cloacal exstrophy 10.3 ATP12A ATP4A

Comorbidity relations with Dyskinesia of Esophagus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dysthymic Disorder
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Irritable Bowel Syndrome
Ischemic Heart Disease Megaesophagus
Mitral Valve Disease Osteoporosis
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Dyskinesia of Esophagus:



Diseases related to Dyskinesia of Esophagus

Symptoms & Phenotypes for Dyskinesia of Esophagus

UMLS symptoms related to Dyskinesia of Esophagus:


spasm

Drugs & Therapeutics for Dyskinesia of Esophagus

Drugs for Dyskinesia of Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
2
Menthol Approved Phase 4,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
3
Methylene blue Approved, Investigational Phase 4,Not Applicable 61-73-4
4
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
5
Dopamine Approved Phase 4,Phase 3,Not Applicable 51-61-6, 62-31-7 681
6
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
7
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
8
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
9
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
10
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
11
Alginic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 9005-32-7
12
Famotidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 76824-35-6 3325
13
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
14
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
15
Ranitidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 66357-59-3, 66357-35-5 3001055
16
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
17
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
18
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
19
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 75614-87-8, 51-45-6 774
20
Ethanol Approved Phase 4 64-17-5 702
21
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
22
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 21645-51-2
23
Magnesium hydroxide Approved, Investigational Phase 4,Phase 1,Not Applicable 1309-42-8
24 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1,Not Applicable 14987-04-3
25
Trimebutine Approved Phase 4 39133-31-8
26
Clozapine Approved Phase 4 5786-21-0 2818
27
Ziprasidone Approved Phase 4 146939-27-7 60854
28
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
29
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
30
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
31
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
32
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
33
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
34
Clarithromycin Approved Phase 4 81103-11-9 84029
35
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
36
Citalopram Approved Phase 4 59729-33-8 2771
37
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
38 Rebamipide Investigational Phase 4 90098-04-7
39 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
40
Lafutidine Investigational Phase 4,Phase 3 118288-08-7 5282136
41
Maleic acid Experimental Phase 4 110-16-7 444266
42 mometasone furoate Phase 4
43 Analgesics Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Cholinergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Coagulants Phase 4,Phase 3,Not Applicable
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Hemostatics Phase 4,Phase 3,Not Applicable
50 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 756)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
3 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
4 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
5 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
6 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
7 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
8 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
9 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
12 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
13 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4 Marinol;Placebo
14 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
15 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
16 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
17 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
18 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
19 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
20 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
21 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
22 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
23 Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Completed NCT00635414 Phase 4 Esomeprazole;Esomeprazole
24 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Dise Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
25 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
26 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
27 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
28 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
29 Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Completed NCT00410592 Phase 4 Esomeprazole 40mg;Pantoprazole 40mg;Lansoprazole 30mg
30 Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response Completed NCT00392002 Phase 4 Esomeprazole
31 PPI Sequencing Study Completed NCT00384592 Phase 4 Esomeprazole
32 CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing Completed NCT00354757 Phase 4 rabeprazole
33 Symptom Adapted Therapy in GERD Patients Completed NCT00343161 Phase 4 esomeprazole;Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
34 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4 Pantoprazole
35 Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
36 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole
37 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
38 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
39 Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) Completed NCT00251732 Phase 4 Standard dose (once daily) PPI plus low-dose antidepressant;Double dose PPI plus evening placebo;Rabeprazole , placebo, placebo
40 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
41 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
42 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
43 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
44 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
45 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
46 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
47 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
48 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
49 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
50 Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying Completed NCT01956682 Phase 4

Search NIH Clinical Center for Dyskinesia of Esophagus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophageal motility disorders

Genetic Tests for Dyskinesia of Esophagus

Anatomical Context for Dyskinesia of Esophagus

MalaCards organs/tissues related to Dyskinesia of Esophagus:

41
Testes, Lung, Bone, Tongue, Tonsil, Thyroid, Adipocyte

Publications for Dyskinesia of Esophagus

Articles related to Dyskinesia of Esophagus:

# Title Authors Year
1
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. ( 23591282 )
2013
2
Esophageal motility disorder achalasia. ( 24136218 )
2013
3
The hidden cause of dysphagia--epiphrenic diverticulum and esophageal motility disorders. ( 22312603 )
2012
4
Achalasia and other esophageal motility disorders. ( 21394546 )
2011
5
A stepwise approach and early clinical experience in peroral endoscopic myotomy for the treatment of achalasia and esophageal motility disorders. ( 21996484 )
2011
6
Primary localized cutaneous nodular amyloidosis associated with CREST (calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia) syndrome. ( 20465653 )
2010
7
Nonspecific esophageal motility disorders may be an early stage of a specific disorder, particularly achalasia. ( 19302217 )
2009
8
Secondary achalasia and other esophageal motility disorders after laparoscopic Nissen fundoplication for gastroesophageal reflux disease. ( 18029886 )
2007
9
Radionuclide imaging for the assessment of esophageal motility disorders in mixed connective tissue disease patients: relation to pulmonary impairment. ( 16984539 )
2006

Variations for Dyskinesia of Esophagus

Expression for Dyskinesia of Esophagus

Search GEO for disease gene expression data for Dyskinesia of Esophagus.

Pathways for Dyskinesia of Esophagus

GO Terms for Dyskinesia of Esophagus

Biological processes related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import GO:0010107 9.37 ATP12A ATP4A
2 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
3 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
4 cellular potassium ion homeostasis GO:0030007 9.16 ATP12A ATP4A
5 sodium ion export across plasma membrane GO:0036376 8.96 ATP12A ATP4A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 8.62 ATP12A ATP4A

Molecular functions related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Dyskinesia of Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....